see more

SOUTH SAN FRANCISCO, CA - APRIL 12: Two women walk by a sign on the Genentech campus April 12, 2005 in South San Francisco, California. Genentech Inc. reported a 61 percent rise in quarterly profit on strong sales of its cancer drugs, and it said it now expects 2005 earnings growth of more than 30 percent, well above the projected profit of 25 percent for 2005. (Photo by Justin Sullivan/Getty Images)

SOUTH SAN FRANCISCO, CA - APRIL 12:  Two women walk by a sign on the Genentech campus April 12, 2005 in South San Francisco, California. Genentech Inc. reported a 61 percent rise in quarterly profit on strong sales of its cancer drugs, and it said it now expects 2005 earnings growth of more than 30 percent, well above the projected profit of 25 percent for 2005.  (Photo by Justin Sullivan/Getty Images)

see more

UNITED STATES - MAY 14: People walk through the Genentech booth during the American Society of Clinical Oncologists convention in Chicago, Illinois, Sunday, June 3, 2007. (Photo by Frank Polich/Bloomberg via Getty Images)

UNITED STATES - MAY 14:  People walk through the Genentech booth during the American Society of Clinical Oncologists convention in Chicago, Illinois, Sunday, June 3, 2007.  (Photo by Frank Polich/Bloomberg via Getty Images)

see more

The Genentech headquarters sits in South San Francisco, California, U.S., on Monday, Dec. 21, 2009. Roche Holding AG's Genentech unit asked U.S. regulators to approve the use of the Lucentis medicine in patients with retinal vein occlusion, the Basel-based company said in an e-mailed statment. Photographer: Chip Chipman/Bloomberg via Getty Images

The Genentech headquarters sits in South San Francisco, California, U.S., on Monday, Dec. 21, 2009. Roche Holding AG's Genentech unit asked U.S. regulators to approve the use of the Lucentis medicine in patients with retinal vein occlusion, the Basel-based company said in an e-mailed statment. Photographer: Chip Chipman/Bloomberg via Getty Images

see more

Genentech's founders Robert Swanson, left, and Herbert Boyer are represented in life like sculptures at the headquarters in South San Francisco, California, U.S., on Monday, Dec. 21, 2009. Roche Holding AG's Genentech unit asked U.S. regulators to approve the use of the Lucentis medicine in patients with retinal vein occlusion, the Basel-based company said in an e-mailed statment. Photographer: Chip Chipman/Bloomberg via Getty Images

Genentech's founders Robert Swanson, left, and Herbert Boyer are represented in life like sculptures at the headquarters in South San Francisco, California, U.S., on Monday, Dec. 21, 2009. Roche Holding AG's Genentech unit asked U.S. regulators to approve the use of the Lucentis medicine in patients with retinal vein occlusion, the Basel-based company said in an e-mailed statment. Photographer: Chip Chipman/Bloomberg via Getty Images

see more

UNITED STATES - FEBRUARY 01: Roche's colon-cancer drug Avastin is displayed in a Cambridge, Massachusetts pharmacy Wednesday, February 1, 2006. Genentech Inc. said requests by U.S. regulators will delay consideration of the colon-cancer drug Avastin as a treatment for breast cancer. (Photo by Jb Reed/Bloomberg via Getty Images)

UNITED STATES - FEBRUARY 01:  Roche's colon-cancer drug Avastin is displayed in a Cambridge, Massachusetts pharmacy Wednesday, February 1, 2006. Genentech Inc. said requests by U.S. regulators will delay consideration of the colon-cancer drug Avastin as a treatment for breast cancer.  (Photo by Jb Reed/Bloomberg via Getty Images)